Acurx announces new data presentations from ongoing ph2 clinical trial program of ibezapolstat for cdi at the 16th biennial congress of the anaerobe society of america

New data link beneficial microbiome changes in ph2a cdi patients to earlier results from ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat new in vitro data show ibezapolstat is effective against high bacterial concentration (inoculum) of c. difficile) and does not induce production of c.
ACXP Ratings Summary
ACXP Quant Ranking